Health
Partnership to develop head and neck cancer vaccine – Mirage News
Professor Christian Ottensmeier (centre)Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company)…
Professor Christian Ottensmeier (centre)
Cancer Research UK, the University of Southampton and Touchlight Genetics (a London based biotechnology company) have announced a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
HNSCC is the UK’s eighth most common cancer, but treatment options are limited and around 4,000 of those affected in the UK die each year. Whilst exis…
-
General21 hours agoLegal fights are brewing over which online social platforms will have to ban under-16s
-
Business20 hours agoHow to spot the next WiseTech or Pro Medicus on the ASX
-
General23 hours agoRussia systematically torturing Ukrainian civilians, UN says
-
Business22 hours agoBHP and these ASX 200 shares could rise 15% to 30%